The specifics, since they change the answer: tirzepatide · forty-two days.
I want a method I can write down and repeat, not a rule of thumb.
I would rather over-engineer this than discover a problem later, within reason.
Which parts of this are load-bearing and which parts are habit?
It helps to be literal here: the titration schedule is a tolerability instrument, not an efficacy one. Nothing in the ladder is there to make the compound work better; every step exists to make the gastrointestinal adverse-event curve survivable.
Holding at a step for longer than four weeks before escalating does appear to reduce cumulative gastrointestinal burden, which is unsurprising given that adverse events cluster in the one to two weeks after each increase. What it does not do is change where you end up, provided you get there.
Missing a dose by three days on a weekly schedule takes the trough down by less than a factor of 1.35, which is well inside the variation you would see between two on-time weeks. Missing it by five or more days is where the label instructions start to differ between agents, and the reason is how close the next scheduled dose is rather than any mechanistic threshold.
The STEP programme escalated semaglutide over sixteen weeks in four-week steps to 2.4 mg weekly, and the trial-product estimand versus treatment-policy estimand distinction accounts for most of the difference between the figures quoted from those papers.
The caveat that matters: dose decisions on a licensed medicine belong with a prescriber, and dose decisions on research-use-only material belong to a category where nobody has any obligation to you at all.
Escalate on tolerability, hold when it costs you, and do not confuse a flattening curve with a failing drug.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThe steady-state arithmetic is worth doing once, because it explains most of what people find confusing about weekly dosing.
Steady state, worked: with a half-life of about seven days and weekly administration, the accumulation ratio is roughly 1/(1 − 0.5) = 2, and you get to within about 97 per cent of steady state after five half-lives, so around thirty-five days — five weeks — after any dose change. A four-week step interval therefore has you escalating at roughly 94 per cent of the previous dose’s steady state, which is close enough to be sensible and not so close as to be conservative.
Extending the interval and reducing the dose are not equivalent manoeuvres. Reducing the dose lowers the whole concentration-time curve proportionally. Extending the interval lowers the average but deepens the trough, and for a compound whose effect on appetite tracks concentration, a deep trough is felt.
One qualification — this is protocol arithmetic and reported practice, not a recommendation. The compounds in question are not approved for human use when supplied for research.
If you take one thing from this: dose rate drives tolerability, dose level drives exposure, and they are separate levers.
Concretely, answering this requires distinguishing the maximum studied dose from the maximum useful dose. The trials established the former. The latter is a per-person question that the trials were not designed to answer.
The argument against splitting a weekly dose is arithmetic rather than ideological. Peak-to-trough ratio for a seven-day half-life compound dosed weekly is about two. Split it into twice-weekly and the ratio falls to roughly 1.4. That is a real reduction in fluctuation and a negligible one in absolute terms, and you have doubled the number of stopper piercings and the number of small-volume measurements, each of which carries its own error.
To be exact about it, the maintenance question turns on what you are maintaining. If the objective is weight maintenance, the withdrawal-extension data suggests that a fraction of the therapeutic dose retains a substantial fraction of the effect. If the objective is the cardiovascular or renal endpoint, the trials that demonstrated those endpoints used the full dose, and extrapolating downward is not supported by anything.
SURMOUNT-4 is the withdrawal trial to read on the maintenance question: after an open-label lead-in, randomised withdrawal produced substantial regain in the placebo arm while continued treatment produced continued loss. It is the cleanest available answer to "what happens if I stop".
Read the actual prescribing information for the agent in question. It is short, specific, and more reliable than any summary of it.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.